Renoprotection in diabetic kidney disease: Can incretin-based therapies deliver?

Research output: Contribution to journalReview articleAcademicpeer-review


Purpose of reviewIncretin-based therapies mimic or augment the gut-hormone glucagon-like peptide (GLP)-1 and, due to their glucose-lowering potential and beneficial safety profile, as well as their cardiovascular safety and/or protection, are prescribed on a large scale to treat individuals with type 2 diabetes (T2D). However, whether the two drug-classes that belong to this category, respectively GLP-1 receptor agonists and dipeptidyl peptidase (DPP)-4 inhibitors, also reduce the risk of diabetic kidney disease (DKD) is at present heavily debated. This review aims to discuss the current evidence.Recent findingsEvidence from land-mark cardiovascular safety trials, conducted in people with T2D at high-cardiovascular risk but with normal kidney function, suggest that both drug-classes have excellent renal safety profiles. In contrast to DPP-4 inhibitors, it seems that GLP-1 receptor agonists reduce albuminuria and possibly induce a reduction of estimated glomerular filtration rate decline. However, the trials were not properly designed to test renal outcomes.SummaryA dedicated renal trial involving a GLP-1 receptor agonist has recently commenced and will answer the question whether these drugs will be effective to reduce DKD. Moreover, ongoing mechanism-of-Action studies are focusing on the renal physiological effects of GLP-1, as the effects on particularly albuminuria reduction remain currently unexplained.
Original languageEnglish
Pages (from-to)103-111
Number of pages9
JournalCurrent opinion in nephrology and hypertension
Issue number1
Publication statusPublished - 1 Jan 2020


  • diabetic kidney disease
  • dipeptidyl peptidase-4 inhibitors
  • glucagon-like peptide-1 receptor agonists
  • incretin-based therapies
  • renoprotection

Cite this